- Home
- NIU vs CRDF Comparison
NIU vs CRDF Comparison
Compare NIU & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIU
- CRDF
- Stock Information
- Founded
- NIU 2014
- CRDF 1999
- Country
- NIU China
- CRDF United States
- Employees
- NIU N/A
- CRDF N/A
- Industry
- NIU Auto Manufacturing
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NIU Consumer Discretionary
- CRDF Health Care
- Exchange
- NIU Nasdaq
- CRDF Nasdaq
- Market Cap
- NIU 141.2M
- CRDF 134.0M
- IPO Year
- NIU 2018
- CRDF N/A
- Fundamental
- Price
- NIU $1.85
- CRDF $2.45
- Analyst Decision
- NIU
- CRDF Strong Buy
- Analyst Count
- NIU 0
- CRDF 3
- Target Price
- NIU N/A
- CRDF $9.33
- AVG Volume (30 Days)
- NIU 511.5K
- CRDF 1.1M
- Earning Date
- NIU 11-18-2024
- CRDF 11-07-2024
- Dividend Yield
- NIU N/A
- CRDF N/A
- EPS Growth
- NIU N/A
- CRDF N/A
- EPS
- NIU N/A
- CRDF N/A
- Revenue
- NIU $420,244,416.00
- CRDF $688,000.00
- Revenue This Year
- NIU $31.46
- CRDF $15.00
- Revenue Next Year
- NIU $29.83
- CRDF N/A
- P/E Ratio
- NIU N/A
- CRDF N/A
- Revenue Growth
- NIU 5.83
- CRDF 49.57
- 52 Week Low
- NIU $1.57
- CRDF $1.15
- 52 Week High
- NIU $3.50
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- NIU 37.37
- CRDF 39.13
- Support Level
- NIU $1.75
- CRDF $2.85
- Resistance Level
- NIU $2.03
- CRDF $2.70
- Average True Range (ATR)
- NIU 0.12
- CRDF 0.37
- MACD
- NIU -0.04
- CRDF -0.12
- Stochastic Oscillator
- NIU 19.67
- CRDF 0.36
About NIU Niu Technologies
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, moped and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").